FDA set a target action date of August 17 for B-MS' lisocabtagene maraleucel

13 February 2020
bristol-myers-squibb-big

US pharma major Bristol-Myers Squibb (NYSE: BMY) today announced that the US Food and Drug Administration has accepted for Priority Review its Biologics License Application (BLA) for lisocabtagene maraleucel (liso-cel).

Liso-cel is the company’s autologous anti-CD19 chimeric antigen receptor (CAR) T-cell immunotherapy with a defined composition of purified CD8+ and CD4+ CAR T cells for the treatment of adult patients with relapsed or refractory (R/R) large B-cell lymphoma after at least two prior therapies. It came into B-MS’s portfolio with the $74 billion acquisition of Celgene and was seen as one of the latter’s most important assets.

The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date of August 17, 2020.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology